Entries by admin

Presentation at NewsMakers

QR Pharma, Inc. to Present Corporate Update at 23rd Annual BioCentury NewsMakers Conference   –One of Fourteen Private Companies Selected to Present–   Berwyn, PA, September 9, 2016 — QR Pharma, Inc., a privately held Phase 2 biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative diseases, today announced that Maria […]

QR Pharma Issues $5.7 M of Series A Preferred Stock

Berwyn, PA., May 26, 2015 — QR Pharma, Inc., a privately held biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative diseases, has closed on $5.7 M of Series A Preferred Stock financing. The round was comprised of $1.1 M of new investments and the conversion of convertible debt. QR Pharma […]

Maria Maccecchini, President and CEO of QR Pharma, Inc. to Serve on Panel with Nobel Laureate, Phillip Sharp at Chemical Heritage Foundation Event

Berwyn, Pennsylvania, May 11, 2015 – Maria Maccecchini, PhD, President and CEO of QR Pharma, Inc. and Philip A. Sharp will be discussing “Secrets of a Science: Challenges and Opportunities of Biomedical Research”. The conversation will span the progress of Science from its beginnings into the future. The event is part of a Heritage Day […]

Peter Davies, the 2015 Recipient of the Potamkin Award, Joins the Scientific Advisory Board of QR Pharma

Berwyn, PA, April 30, 2015: QR Pharma, Inc., a privately held biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative diseases, announced the election of Dr. Peter Davies to its Scientific Advisory Board. This appointment follows the recent Series A funding. “We are thrilled to have Peter on our Scientific […]

QR Pharma Receives US Patent 8,691,864 to Treat Dementia

Berwyn, Pa., April 8, 2015/PRNewswire/ — QR Pharma, Inc., a privately held biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative diseases, announced that it was issued U.S. Patent No. 8,691,864, “Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia” by the U.S. Patent and Trademark Office. The “864 patent […]

QR Pharma Begins Collaboration on Posiphen® and Huntington’s Disease

Berwyn, PA, February 3, 2015 – QR Pharma, Inc.(QR) announced today a new collaborative research agreement with The Rockefeller University aimed at developing a treatment for Huntington’s disease (HD). The collaborationwill focus onpreclinical research involvingQR’s lead drug candidate,Posiphen®.Investigators at Rockefeller will conduct experiments in stem cell culture models of HD to determine if Posiphen lowers […]

QR Pharma Announces the Appointment of New Chairman and New Board Member

Berwyn, Pa., January 6, 2015: QR Pharma, Inc., a privately held biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative diseases, announced the election of Mr. Michael Hoffman as Chairman of the Board of Directors and Mr. Dhesh Govender as Director. These appointments follow the recent opening of a Series […]